BDX Becton, Dickinson and Company Common Stock
NYSE · Health Care · View on SEC EDGAR ↗ 10-K/10-Q Aug 6, 2026
$196.39
· of 52w range
· above low
· to high
$127.5952w low
$200.4752w high
P/E (TTM)
59.3
EPS (TTM)
$3.31
Revenue (TTM)
$20.84B
your badges
52W Range
$128–$200
Analyst Rating
HOLD
Price Target
$196
P/E
59.3
ROE
3.8%
Net Profit Margin
4.5%
Your badge strip is empty — pin a metric anywhere on this page.
BDX Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$196.39
P/E (TTM)
59.3
EPS (TTM)
$3.31
Revenue (TTM)
$20.84B
ROE (TTM)
3.8%
Debt/Equity (MRQ)
0.6
52W Range
$128–$200
BDX Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
range
bars
Bar granularity adapts to the selected period — hover the chart to see open/high/low/close for a bar.
Stock splits
| Ex-date | Split | Type |
|---|---|---|
| Feb. 10, 2026 | 159-for-125 | Forward |
| April 1, 2022 | 41-for-40 | Forward |
| Aug. 21, 1998 | 2-for-1 | Forward |
| Aug. 16, 1996 | 2-for-1 | Forward |
| March 1, 1993 | 2-for-1 | Forward |
| March 3, 1986 | 2-for-1 | Forward |
About Becton, Dickinson and Company Common Stock Company overview from Wikipedia
Becton, Dickinson and Company (BD; also Becton Dickinson or Becton) is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain areas.
BD is ranked #211 in the 2024 Fortune 500 list based on its revenues for the fiscal year ending September 30, 2023.
History
The company was founded in 1897 in New York City by Maxwell Becton and Fairleigh S. Dickinson. It later moved its headquarters to New Jersey.
In 2004, BD agreed to pay out US$100 million to settle allegations from competitor Retractable Technologies that it had engaged in anti-competitive behavior to prevent the distribution of Retractable's syringes, which are designed to prevent needlestick injury. The lawsuit touched off a series of legal conflicts between the companies. Retractable would accuse BD of patent infringement after BD released a retractable needle of its own. Later Retractable would claim BD was falsely advertising its own brand of retractable needle as the “world’s sharpest needle”.
In October 2014, the company agreed to acquire CareFusion for a price of US$12.2 billion in cash and stock.
In April 2017, Becton, Dickinson and Company announced it would acquire C. R. Bard. The transaction was completed later that year, and the company became a wholly-owned subsidiary of BD, rebranded as Bard.
In May 2021, BD announced that it would spin off its diabetes care business (https://investors.bd.com/news-events/press-releases/detail/85/bd-announces-completion-of-embecta-corp-spinoff). The spinoff was completed on April 1, 2022, to form Embecta Corporation. Embecta Corporation is a standalone public company focused on diabetes care. The name "embecta" represents the company's commitment to people living with diabetes and its corporate heritage, with the "em-" prefix evoking empathy for people living with diabetes and the empowerment of the new company and the "bect" imbibed from Becton. Becton, Dickinson and Company entered into an agreement with Embecta Corporation to be their sole supplier of cannulas through 2032. This agreement protects patents and intellectual properties of both companies ensuring the quality and integrity of Embecta Corporation's cannulas used in their products.
In July 2021, BD announced it would acquire surgical scaffold maker Tepha, after having acquired Velano Vascular earlier the same month.
In 2024, BD announced it would acquire Edwards Lifesciences' critical care unit for $4.2 billion.
Finances
For the fiscal year 2017, Becton Dickinson reported earnings of US$1.030 billion, with an annual revenue of US$12.093 billion, an increase of 10.5% over the previous fiscal cycle. Becton Dickinson's shares traded at over US$192 per share, and its market capitalization was valued at over US$63 billion in November 2018.
Business segments
Currently there are three business segments.
BD Medical
In certain places, BD Medical also offers consulting and analytics related services. BD Medical's Consulting services are primarily targeted at hospitals, healthcare systems and networks of healthcare providers.
BD Life Sciences
Business units include Biosciences and Integrated Diagnostic Solutions.
Offerings include preanalytical solutions for sample management; immunology research, including flow cytometry and multiomics tools; microbiology and molecular diagnostics; lab automation and informatics; and differentiated reagents and assays.
In February 2026, BD Life Sciences was spun out and combined with the businesses of Waters Corporation.
BD Interventional
The company's line of plastic conical screwtop test tubes, known as 'Falcon tubes', is popular and the term is sometimes used as a generic term for such tubes.
Environmental and social track record
As of February 2010, BD was ranked 18th in the EPA Fortune 500 List of Green Power Purchasers. BD was also listed among the top 100 companies in Newsweek's 2009 Green Rankings ranking of the 500 largest American corporations based on environmental performance, policies, and reputation. BD placed third in the health care sector and 83rd overall. In addition, BD has been a component of the Dow Jones Sustainability World Index and the Dow Jones Sustainability North America Index for the four and five consecutive years, respectively.
Pfitzer et al. (2013) identify BD's development of a needleless injection system as an example of leading businesses' role in creating shared value.
Health and safety issues
In April 2016, the Occupational Safety and Health Administration fined BD US$112,700 for safety violations. They found repeat and serious violations of health and safety law that had resulted in two employees having partial finger amputations.
In 2020, C.R. Bard, Inc. and its parent company BD were fined $60 million USD for failing to adequately inform patients about health risks related to their transvaginal mesh devices.
Recalls
2007 Discardit II incident in Poland
In mid-2007, the firm's Discardit II series of syringes numbered 0607186 was withdrawn from hospitals and other medical services around Poland, about half a year after the discovery of remains of dark dust in some syringes, which were alleged to have been from this series. The newspaper Dziennik Online claimed that other series such as 06022444, 0603266, and 0607297 were also suspected of being contaminated. BD recalled and tested the syringes in question, and revealed sterile particulates in 0.013 percent of the products.
2010 Q-Syte Luer and IV Catheter partial recall
In February 2010 BD announced a voluntary product recall of certain lots of BD Q-Syte Luer Access Devices and BD Nexiva Closed IV Catheter Systems. BD stated that the use of the affected devices may cause an air embolism or leakage of blood and/or therapy, which may result in serious injury or death. The approximately 2.8 million BD Q-Syte and 2.9 million BD Nexiva units containing 5 million BD Q-Syte devices that were recalled were distributed in the United States, Asia, Canada, Europe, Mexico, the Middle East, South Africa, and South America. The recall was initiated on Oct. 28, 2009 after BD received complaints of problems due to air entry through a part of the device. BD stated that the cause of the problem was manufacturing deviation and claimed that it corrected the problem. BD announced that it notified customers about the recall by letter and has been working with the U.S. Food and Drug Administration and worldwide health agencies to coordinate recall activities.
2021 IV Giving Sets
In March 2021 BD announced a recall of infusion sets for CC, GP, VP, GW/GW800, SE, and IVAC 590 Alaris Pumps and gravity infusion sets and connectors following the news that a supplier falsified sterilisation documents going back ten years.
Lawsuits
In October 2024, BD agreed to settle around 38,000 US lawsuits brought by plaintiffs who claimed they were injured by BD's hernia meshes.
In December 2025, BD was sued by Tela Bio Inc., makers of a ovine forestomach matrix hernia mesh, who alleged that BD engaged in anticompetitive practices to push Tela out of the market for surgical meshes while raising prices for providers and patients.
Viral Orlando delivery driver incident
On September 6, 2026, in Orlando, Florida, a man identified on social media as Eric Smith, reportedly an employee of medical technology company Becton, Dickinson and Company (BD), drew widespread criticism after a confrontation with a food-delivery worker was captured on video and circulated online.
The video gained significant attention after being shared by social-media commentator Tizzyent on Instagram. During the encounter, the man was recorded making racist remarks toward the delivery worker, demanding her name. The footage subsequently went viral, generating calls on social media for BD to investigate the incident and address the alleged conduct of its employee.
Social-media users subsequently identified the man as Eric Smith and linked him to BD.
Incident recap
The incident reportedly occurred around 8:30 p.m. in Orlando, Florida, while a female delivery driver was making a food delivery. According to the driver, a man confronted her for allegedly blocking the road during her delivery, before questioning her immigration status, making remarks about "illegal immigrants," threatening to call ICE, and saying he would follow her.
The driver said she initially apologized and did not provoke the confrontation. Video of the encounter was later shared by Tizzyent on Instagram, where it went viral and drew widespread criticism.
Source: Wikipedia, CC BY-SA 4.0 · View on Wikipedia ↗
sectorHealth Care
industryHealth Care
employees72,000
countryUS
10-Year Performance Revenue, net income, margins and EPS trends
Revenue$21.84B2016-09-30 → 2025-09-30
EPS$5.822016-09-30 → 2025-09-30
Free Cash Flow$2.67B2016-09-30 → 2025-09-30
Net margin4.5%2016-09-30 → 2025-09-30
Valuation & Ratios
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
| Metric | 5Y trend | BDX | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| P/E (TTM) | 59.35Y avg ≈31.2 | ≈31.2 | · | · | |
| PEG Ratio | ≈3.6 | · | · | · |
Peer median is calculated on a standardized basis per metric and may not always match the TTM/MRQ basis shown for this stock.
Profitability Gross, operating and net margins; ROE, ROA, ROIC
| Metric | 5Y trend | BDX | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Operating Margin (TTM) | 9.6%5Y avg ≈12.1% | ≈12.1% | · | · | |
| EBITDA Margin (TTM) | 21.0%5Y avg ≈23.6% | ≈23.6% | · | · | |
| Pretax Margin (TTM) | 7.2%5Y avg ≈9.5% | ≈9.5% | · | · | |
| Net Profit Margin (TTM) | 4.5%5Y avg ≈8.7% | ≈8.7% | · | · | |
| ROA (TTM) | 1.8%5Y avg ≈3.2% | ≈3.2% | · | · | |
| ROE (TTM) | 3.8%5Y avg ≈7.0% | ≈7.0% | · | · | |
| ROIC | 5.3%5Y avg ≈5.3% | ≈5.3% | · | · |
Financial Health Debt, liquidity, solvency — balance sheet strength
| Metric | 5Y trend | BDX | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Debt / Equity (MRQ) | 0.65Y avg ≈0.6 | ≈0.6 | · | · | |
| Current Ratio (MRQ) | 0.95Y avg ≈1.2 | ≈1.2 | · | · | |
| Quick Ratio | 0.45Y avg ≈0.5 | ≈0.5 | · | · | |
| Long-Term Debt / Equity (MRQ) | 0.65Y avg ≈0.6 | ≈0.6 | · | · | |
| Interest Coverage | 4.25Y avg ≈5.0 | ≈5.0 | · | · |
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
| Metric | 5Y trend | BDX | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Revenue YoY | 8.2%5Y avg ≈6.5% | ≈6.5% | · | · | |
| Revenue CAGR 3Y | 5.0%5Y avg ≈4.4% | ≈4.4% | · | · | |
| Revenue CAGR 5Y | 6.3% | · | · | · | |
| EPS YoY | -0.68%5Y avg ≈28.1% | ≈28.1% | · | · | |
| Net Income YoY | -1.6%5Y avg ≈24.2% | ≈24.2% | · | · | |
| EPS CAGR 3Y | -0.34%5Y avg ≈5.6% | ≈5.6% | · | · | |
| EPS CAGR 5Y | 16.5% | · | · | · | |
| Net Income CAGR 3Y | -1.9%5Y avg ≈3.6% | ≈3.6% | · | · | |
| Net Income CAGR 5Y | 13.9% | · | · | · |
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
| Metric | 5Y trend | BDX | 5Y avg | Peer Median | Verdict |
|---|---|---|---|---|---|
| Asset Turnover | 0.45Y avg ≈0.4 | ≈0.4 | · | · | |
| Inventory Turnover | 3.15Y avg ≈3.4 | ≈3.4 | · | · | |
| Receivables Turnover | 7.25Y avg ≈7.9 | ≈7.9 | · | · | |
| Revenue / Employee | ≈$303.3K | · | · | · |
value · ≈ 5Y avg · industry median · verdict relative to median
Dividends Yield, payout ratio, dividend history, 5Y CAGR
Payout Ratio71.3%
Annualized Payout≈$4.20
5Y Div CAGR≈6.2%
Growth Streak≈41
| Ex-date | Amount | Currency | Yield |
|---|---|---|---|
| Sep 9, 2026 | $1.05 | USD | ≈2.2% |
| Jun 9, 2026 | $1.05 | USD | ≈2.5% |
| Mar 10, 2026 | $1.05 | USD | ≈2.1% |
| Dec 8, 2025 | $0.83 | USD | ≈2.2% |
| Sep 8, 2025 | $0.82 | USD | ≈2.2% |
| Jun 9, 2025 | $0.82 | USD | ≈2.4% |
| Mar 10, 2025 | $0.82 | USD | ≈1.7% |
| Dec 9, 2024 | $0.82 | USD | ≈1.7% |
| Sep 9, 2024 | $0.75 | USD | ≈1.6% |
| Jun 10, 2024 | $0.75 | USD | ≈1.6% |
| Mar 7, 2024 | $0.75 | USD | ≈1.6% |
| Dec 7, 2023 | $0.75 | USD | ≈1.6% |
| Sep 7, 2023 | $0.72 | USD | ≈1.4% |
| Jun 8, 2023 | $0.72 | USD | ≈1.4% |
| Mar 9, 2023 | $0.72 | USD | ≈1.5% |
| Dec 8, 2022 | $0.72 | USD | ≈1.4% |
| Sep 8, 2022 | $0.68 | USD | ≈1.3% |
| Jun 8, 2022 | $0.68 | USD | ≈1.3% |
| Mar 9, 2022 | $0.67 | USD | ≈1.3% |
| Dec 9, 2021 | $0.67 | USD | ≈1.4% |
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
2.7%
Next Report
Nov 05, 2026
| Period | Report | EPS Actual | EPS Est | Surprise |
|---|---|---|---|---|
| June 30, 2026 | $3.23 | $3.17 | 1.8% | |
| March 31, 2026 | $2.90 | $2.80 | 3.5% | |
| Dec. 31, 2025 | $2.91 | $2.84 | 2.4% | |
| Sept. 30, 2025 | $3.96 | $3.96 | -0.05% | |
| June 30, 2025 | $3.68 | $3.44 | 7.1% | |
| March 31, 2025 | $3.35 | $3.31 | 1.1% |
Full Fundamentals All metrics by year — income statement, balance sheet, cash flow
Income Statement
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $21.84B | $20.18B | $19.37B | $18.87B | $19.13B | $16.07B | $17.29B | $15.98B | $12.09B | $12.48B | $10.28B | $8.45B | |
| Cost of Revenue | $11.91B | $11.05B | $11.20B | $10.39B | $10.50B | $9.28B | $9.00B | $8.71B | $6.13B | $6.49B | $5.59B | $4.14B | |
| Gross Profit | · | · | · | · | · | $7.58B | $8.29B | $7.27B | $5.94B | $5.99B | $4.70B | $4.30B | |
| R&D Expense | $1.26B | $1.19B | $1.24B | $1.26B | $1.28B | $1.04B | $1.06B | $1.00B | $770M | $828M | $632M | $550M | |
| SG&A Expense | $5.28B | $4.86B | $4.72B | $4.71B | $4.72B | $4.18B | $4.33B | $4.02B | $2.91B | $3.00B | $2.56B | $2.15B | |
| Operating Expenses | $19.26B | $17.78B | $17.26B | $16.59B | $16.88B | $15.16B | $15.53B | $14.47B | $10.57B | $11.05B | $9.21B | $6.84B | |
| Operating Income | $2.58B | $2.40B | $2.11B | $2.28B | $2.25B | $912M | $1.76B | $1.51B | $1.52B | $1.43B | $1.07B | $1.61B | |
| Interest Expense | $613M | $528M | $452M | $398M | $469M | $528M | $639M | $706M | $521M | $388M | $371M | $135M | |
| Interest Income | $38M | $163M | $49M | $16M | $9M | $7M | $12M | $65M | $76M | $21M | $15M | $46M | |
| Other Non-op | $-123M | $-28M | $-46M | $-117M | $-99M | $23M | $43M | $305M | $-101M | $11M | $21M | $5M | |
| Pretax Income | $1.88B | $2.00B | $1.66B | $1.78B | $1.69B | $414M | $1.18B | $1.17B | $976M | $1.07B | $739M | $1.52B | |
| Income Tax | $203M | $300M | $132M | $148M | $88M | $62M | $-57M | $862M | $-124M | $97M | $44M | $337M | |
| Net Income | $1.68B | $1.71B | $1.48B | $1.78B | $2.09B | $874M | $1.23B | $311M | $1.10B | $976M | $695M | $1.19B | |
| EPS (Basic) | $5.83 | $5.88 | $4.97 | $5.93 | $6.92 | $2.75 | $4.01 | $0.62 | $4.70 | $4.59 | $3.43 | $6.13 | |
| EPS (Diluted) | $5.82 | $5.86 | $4.94 | $5.88 | $6.85 | $2.71 | $3.94 | $0.60 | $4.60 | $4.49 | $3.35 | $5.99 | |
| Shares (Basic) | 287,648,000 | 289,763,000 | 286,282,000 | 285,005,000 | 289,288,000 | 278,971,000 | 269,943,000 | 258,354,000 | 218,943,000 | 212,702,000 | 202,537,000 | 193,299,000 | |
| Shares (Diluted) | 288,509,000 | 291,009,000 | 288,392,000 | 287,364,000 | 292,089,000 | 282,402,000 | 274,775,000 | 264,621,000 | 223,588,000 | 217,536,000 | 207,509,000 | 197,709,000 | |
| EBITDA | $5.04B | $4.68B | $4.40B | $4.51B | $5.07B | $3.64B | $4.01B | $3.48B | $2.57B | $2.54B | $1.97B | $2.17B |
Balance Sheet
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $567M | $1.72B | $1.42B | $1.01B | $2.28B | $2.83B | $536M | $1.14B | $14.18B | $1.54B | $1.42B | $1.86B | |
| Receivables | $2.40B | $3.03B | $2.53B | $2.19B | $2.35B | $2.40B | $2.35B | $2.32B | $1.74B | $1.62B | $1.62B | $1.19B | |
| Inventory | $3.15B | $3.84B | $3.27B | $3.22B | $2.74B | $2.74B | $2.58B | $2.45B | $1.82B | $1.72B | $1.96B | $1.50B | |
| Other Current Assets | $1.38B | $1.29B | $1.38B | $1.56B | $1.05B | $891M | $1.12B | $1.25B | $871M | $480M | $563M | $698M | |
| Current Assets | $9.26B | $10.47B | $8.68B | $8.14B | $8.84B | $8.97B | $6.66B | $7.41B | $18.63B | $6.37B | $5.66B | $6.13B | |
| PP&E (Net) | $6.38B | $6.82B | $6.56B | $6.01B | $6.00B | $5.92B | $5.66B | $5.38B | $4.64B | $3.90B | $4.06B | $3.60B | |
| PP&E (Gross) | $13.66B | $14.38B | $13.58B | $12.41B | $12.09B | $11.92B | $11.13B | $10.48B | $9.39B | $8.42B | $8.28B | $7.76B | |
| Accum. Depreciation | $7.27B | $7.56B | $7.02B | $6.40B | $6.09B | $6.00B | $5.47B | $5.11B | $4.75B | $4.52B | $4.22B | $4.16B | |
| Goodwill | $25.96B | $26.46B | $24.52B | $24.62B | $23.89B | $23.60B | $23.38B | $23.60B | $7.56B | $7.42B | $7.54B | $1.09B | |
| Intangibles | $9.23B | $10.87B | $10.90B | $12.26B | $12.73B | $13.77B | · | · | · | · | · | · | |
| Other Non-current Assets | $2.38B | $2.62B | $2.08B | $1.85B | $1.95B | $1.69B | $1.09B | $1.08B | $1.01B | $824M | $717M | $488M | |
| Total Assets | $55.33B | $57.29B | $52.78B | $52.93B | $53.87B | $54.01B | $51.77B | $53.90B | $37.73B | $25.59B | $26.48B | $12.38B | |
| Accounts Payable | $6.11B | $1.90B | $1.64B | $1.70B | $1.74B | $1.35B | $1.09B | $1.11B | $797M | $665M | $631M | $401M | |
| Accrued Liabilities | $3.10B | $3.48B | $2.60B | $2.60B | $2.87B | $2.64B | $2.13B | $2.25B | $1.39B | $1.57B | $1.62B | $1.05B | |
| Current Liabilities | $8.31B | $8.96B | $6.64B | $7.81B | $6.63B | $5.84B | $5.66B | $7.22B | $3.34B | $4.40B | $4.38B | $2.23B | |
| Capital Leases | $704M | $667M | $414M | $384M | $344M | $336M | · | · | · | · | · | · | |
| Deferred Tax | · | · | · | · | · | · | · | · | · | · | $1.95B | $130M | |
| Other Non-current Liabilities | $2.63B | $3.56B | $4.58B | $5.05B | $5.21B | $5.75B | $5.68B | $5.74B | $1.61B | $1.68B | $2.43B | $383M | |
| Long-term Debt | · | · | · | · | · | · | · | · | · | · | $12.12B | $3.77B | |
| Total Debt | $17.62B | $17.94B | $14.74B | $13.89B | $17.11B | $17.22B | $18.08B | $18.89B | $18.67B | $10.55B | $12.12B | $3.77B | |
| Common Stock | $371M | $371M | $371M | $365M | $365M | $365M | $347M | $347M | $347M | $333M | $333M | $333M | |
| Retained Earnings | $16.62B | $16.14B | $15.54B | $15.16B | $13.83B | $12.79B | $12.91B | $12.60B | $13.11B | $12.73B | $12.31B | $12.11B | |
| Treasury Stock | $9.81B | $8.81B | $8.30B | $8.33B | $7.72B | $6.14B | $6.19B | $6.24B | $8.43B | $8.21B | $8.24B | $8.60B | |
| AOCI | $-1.90B | $-1.73B | $-1.55B | $-1.49B | $-2.09B | $-2.55B | $-2.28B | $-1.91B | $-1.72B | $-1.93B | $-1.74B | $-1.00B | |
| Stockholders' Equity | $25.39B | $25.89B | $25.80B | $25.28B | $23.68B | $23.77B | $21.08B | $20.99B | $12.95B | $7.63B | $7.16B | $5.05B | |
| Liabilities + Equity | $55.33B | $57.29B | $52.78B | $52.93B | $53.87B | $54.01B | $51.77B | $53.90B | $37.73B | $25.59B | $26.48B | $12.45B |
Cash Flow
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $2.46B | $2.29B | $2.29B | $2.23B | $2.23B | $2.12B | $2.25B | $1.98B | $1.09B | $1.11B | $891M | $562M | |
| Stock-based Comp | $258M | $247M | $259M | $233M | $229M | $236M | $261M | $322M | $174M | $196M | $166M | $113M | |
| Deferred Tax | $-474M | $-211M | $-622M | $-129M | $-280M | $-285M | $-633M | $-262M | $-74M | $-519M | $-274M | $-94M | |
| Amort. of Intangibles | $1.59B | $1.47B | $1.47B | $1.43B | $1.40B | $1.38B | $1.50B | $1.25B | $553M | $552M | $346M | $84M | |
| Restructuring | $275M | $387M | $239M | $123M | $44M | $84M | · | · | $85M | $526M | $271M | · | |
| Other Non-cash | $-494M | $-183M | $-419M | $-1.64B | $333M | $553M | $216M | $516M | $262M | $792M | $252M | $-20M | |
| Operating Cash Flow | $3.43B | $3.84B | $2.99B | $2.47B | $4.13B | $2.94B | $3.33B | $2.87B | $2.55B | $2.56B | $1.73B | $1.75B | |
| CapEx | $760M | $725M | $874M | $973M | $1.19B | $769M | $957M | $895M | $727M | $693M | $596M | $592M | |
| Investing Cash Flow | $-818M | $-5.51B | $-716M | · | $-1.88B | $-1.23B | $-741M | $-15.73B | $-883M | $-669M | $-8.32B | $-948M | |
| Debt Issued | $0 | $4.52B | $1.66B | $497M | $4.87B | $3.39B | $2.22B | $5.09B | $11.46B | $0 | $6.16B | $0 | |
| Net Debt Issued | $-1.79B | $3.38B | $-493M | $-308M | $-243M | $-1.27B | $-2.52B | $1.09B | $7.48B | $-752M | $6.16B | · | |
| Stock Repurchased | $1.00B | $500M | $0 | $500M | $1.75B | $0 | $0 | $0 | $220M | $0 | $0 | $400M | |
| Net Stock Activity | $-1.00B | $-500M | $0 | $-500M | $-1.75B | · | $0 | $0 | $-220M | $0 | $0 | $-400M | |
| Dividends Paid | $1.20B | $1.10B | $1.11B | $1.08B | $1.05B | $1.03B | $984M | $927M | $677M | $562M | $485M | $421M | |
| Financing Cash Flow | $-3.62B | $2.09B | $-1.96B | · | $-3.31B | $22M | $-3.22B | $-58M | $10.98B | $-1.76B | $6.19B | $-807M | |
| Net Change in Cash | $-1.00B | $375M | $322M | $-1.23B | $-525M | $2.33B | $-646M | $-12.94B | $12.64B | $117M | $-436M | $-29M | |
| Taxes Paid | $599M | $653M | $629M | $532M | $671M | $523M | $536M | $235M | $265M | $218M | $240M | $330M | |
| Free Cash Flow | $2.67B | $3.12B | $2.12B | $1.50B | $3.42B | $2.73B | $2.37B | $1.97B | $1.82B | $1.87B | $1.13B | $1.15B | |
| Levered FCF | $2.12B | $2.67B | $1.70B | $1.13B | $2.98B | $2.26B | $1.70B | $1.78B | $1.24B | $1.51B | $785M | $1.05B |
Profitability
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | · | · | · | 44.3% | 47.9% | 45.4% | 49.1% | 48.0% | 45.7% | · | |
| Operating Margin | 11.8% | 11.9% | 10.9% | 12.1% | 13.8% | 8.7% | 10.2% | 9.4% | 12.2% | 11.5% | 10.4% | 19.0% | |
| Net Margin | 7.7% | 8.5% | 7.7% | 9.4% | 10.3% | 5.1% | 7.1% | 1.9% | 9.1% | 7.8% | 6.8% | 14.0% | |
| Pretax Margin | 8.6% | 9.9% | 8.6% | 9.4% | 11.1% | 5.8% | 6.8% | 7.3% | 8.1% | 8.6% | 7.2% | 18.0% | |
| EBITDA Margin | 23.1% | 23.2% | 22.7% | 23.9% | 25.1% | 21.2% | 23.2% | 21.7% | 21.2% | 20.4% | 19.1% | 25.7% | |
| ROA | 3.0% | 3.1% | 2.8% | 3.3% | 3.9% | 1.7% | 2.3% | 0.68% | 3.5% | 3.8% | 3.5% | 9.6% | |
| ROE | 6.5% | 6.6% | 5.8% | 7.3% | 8.8% | 3.9% | 5.9% | 1.8% | 10.7% | 13.2% | 11.4% | 23.5% | |
| ROIC | 5.3% | 4.7% | 4.8% | 5.3% | 6.4% | 3.2% | 4.7% | 1.0% | 5.3% | 7.1% | 5.2% | 14.2% |
Liquidity & Solvency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.1 | 1.2 | 1.3 | 1.0 | 1.3 | 1.5 | 1.2 | 1.0 | 5.6 | 1.4 | 1.4 | 2.7 | |
| Quick Ratio | 0.4 | 0.5 | 0.6 | 0.4 | 0.7 | 0.9 | 0.5 | 0.5 | 4.8 | 0.7 | 0.7 | 1.4 | |
| Debt / Equity | 0.7 | 0.7 | 0.6 | 0.5 | 0.7 | 0.7 | 0.9 | 0.9 | 1.4 | 1.4 | 1.7 | 0.7 | |
| LT Debt / Equity | 0.7 | 0.7 | 0.6 | 0.5 | 0.7 | 0.7 | 0.9 | 0.9 | 1.4 | 1.4 | 1.6 | 0.7 | |
| Interest Coverage | 4.2 | 4.5 | 4.7 | 5.7 | 6.0 | 2.8 | 2.8 | 2.1 | 2.8 | 3.7 | 2.9 | 11.9 |
Efficiency
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.4 | 0.4 | 0.4 | 0.4 | 0.3 | 0.3 | 0.3 | 0.4 | 0.5 | 0.5 | 0.7 | |
| Inventory Turnover | 3.1 | 3.1 | 3.4 | 3.5 | 3.9 | 3.6 | 3.6 | 4.1 | 3.5 | 3.5 | 3.2 | 2.9 | |
| Receivables Turnover | 7.2 | 7.2 | 8.2 | 8.3 | 8.3 | 7.2 | 7.4 | 7.9 | 7.2 | 7.7 | 7.3 | 7.0 |
Per Share
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue / Share | $75.70 | $69.34 | $67.17 | $65.67 | $69.32 | $60.61 | $62.92 | $60.40 | $54.09 | $57.38 | $49.55 | $42.72 | |
| Cash Flow / Share | $11.89 | $13.21 | $10.37 | $8.60 | $15.91 | $12.53 | $12.12 | $10.83 | $11.40 | $11.76 | $8.34 | $8.83 | |
| Dividend Paid / Share | $4.16 | $3.80 | $3.64 | $3.48 | $3.32 | $3.16 | $3.08 | $3.00 | $2.92 | $2.64 | $2.40 | $2.18 | |
| EPS (TTM) | $5.82 | $5.86 | $4.94 | $5.88 | $6.85 | $2.71 | $3.94 | $0.60 | $4.60 | $4.49 | $3.35 | $5.99 |
Growth Rates
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 8.2% | 4.2% | 2.7% | -1.4% | 19.0% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 5.0% | 1.8% | 6.4% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 6.3% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | -0.68% | 18.6% | -16.0% | -14.2% | 152.8% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | -0.34% | -5.1% | 22.2% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 16.5% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | -1.6% | 14.9% | -16.6% | -15.0% | 139.4% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | -1.9% | -6.6% | 19.3% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 13.9% | · | · | · | · | · | · | · | · | · | · | · | |
| Dividends Paid CAGR 5Y | 3.1% | · | · | · | · | · | · | · | · | · | · | · |
Valuation (TTM)
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $21.84B | $20.18B | $19.37B | $18.87B | $19.13B | $16.07B | $17.29B | $15.98B | $12.09B | $12.48B | $10.28B | $8.45B | |
| Net Income TTM | $1.68B | $1.71B | $1.48B | $1.78B | $2.09B | $874M | $1.23B | $311M | $1.10B | $976M | $695M | $1.19B | |
| P/E | 25.3 | 32.3 | 41.1 | 29.8 | 27.5 | 65.9 | 49.2 | 333.6 | 32.7 | 30.7 | 30.4 | 14.6 | |
| Earnings Yield | 4.0% | 3.1% | 2.4% | 3.4% | 3.6% | 1.5% | 2.0% | 0.30% | 3.1% | 3.3% | 3.3% | 6.9% | |
| Payout Ratio | 71.3% | 64.5% | 75.1% | 60.8% | 50.1% | 117.4% | 79.8% | 298.1% | 61.6% | 57.6% | 69.8% | 35.5% | |
| Annual Payout | $1.20B | $1.10B | $1.11B | $1.08B | $1.05B | $1.03B | $984M | $927M | $677M | $562M | $485M | $421M |
Income Statement
| Metric | Trend | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.98B | $4.71B | $5.25B | $5.89B | $4.73B | $4.48B | $5.17B | $5.44B | $4.99B | $5.04B | $4.71B | $5.09B | $4.88B | $4.82B | $4.59B | $4.76B | |
| Cost of Revenue | $2.67B | $2.56B | $2.84B | $3.09B | $2.49B | $2.62B | $2.93B | $2.95B | $2.68B | $2.74B | $2.68B | $3.38B | $2.78B | $2.59B | $2.45B | $2.68B | |
| R&D Expense | $258M | $249M | $306M | $323M | $230M | $232M | $343M | $302M | $299M | $299M | $290M | $281M | $306M | $337M | $313M | $300M | |
| SG&A Expense | $1.26B | $1.21B | $1.39B | $1.37B | $1.16B | $1.12B | $1.32B | $1.25B | $1.20B | $1.19B | $1.21B | $1.14B | $1.19B | $1.21B | $1.19B | $1.18B | |
| Operating Expenses | $4.32B | $4.62B | $4.70B | $5.19B | $3.99B | $4.10B | $4.71B | $4.81B | $4.39B | $4.31B | $4.27B | $4.74B | $4.33B | $4.19B | $4.00B | $4.27B | |
| Operating Income | $663M | $93M | $552M | $698M | $739M | $383M | $453M | $622M | $602M | $734M | $439M | $349M | $549M | $628M | $585M | $489M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $125M | $111M | $113M | $119M | $118M | $102M | $104M | |
| Interest Income | $4M | $9M | $4M | $5M | $4M | $5M | $23M | $55M | $48M | $26M | $34M | $9M | $24M | $10M | $6M | $7M | |
| Other Non-op | $19M | $86M | $-10M | $-36M | $-22M | $-36M | $-16M | $-9M | $-13M | $-2M | $-4M | $-63M | $17M | $8M | $-8M | $-73M | |
| Pretax Income | $554M | $39M | $393M | $509M | $569M | $201M | $306M | $513M | $500M | $633M | $359M | $181M | $471M | $529M | $481M | $320M | |
| Income Tax | $102M | $76M | $11M | $16M | $118M | $43M | $3M | $114M | $13M | $96M | $77M | $28M | $64M | $68M | $-28M | $33M | |
| Net Income | $377M | $-311M | $382M | $493M | $574M | $308M | $303M | $400M | $487M | $537M | $281M | $108M | $407M | $460M | $509M | $288M | |
| EPS (Basic) | $1.37 | $-1.11 | $1.34 | $1.71 | $2.00 | $1.07 | $1.05 | $1.38 | $1.68 | $1.85 | $0.97 | $0.35 | $1.37 | $1.54 | $1.71 | $0.94 | |
| EPS (Diluted) | $1.37 | $-1.11 | $1.34 | $1.71 | $2.00 | $1.07 | $1.04 | $1.37 | $1.68 | $1.85 | $0.96 | $0.35 | $1.36 | $1.53 | $1.70 | $0.92 | |
| Shares (Basic) | 274,788,000 | 280,640,000 | 285,582,000 | · | 287,170,000 | 287,293,000 | 289,505,000 | · | 289,562,000 | 289,518,000 | 290,113,000 | · | 286,317,000 | 284,292,000 | 283,887,000 | · | |
| Shares (Diluted) | 275,158,000 | 280,640,000 | 285,845,000 | · | 287,223,000 | 287,737,000 | 290,389,000 | · | 290,253,000 | 290,344,000 | 291,398,000 | · | 287,944,000 | 285,645,000 | 285,340,000 | · | |
| EBITDA | $1.23B | $656M | $1.17B | · | $882M | $546M | $1.06B | · | $602M | $734M | $1.00B | · | $549M | $628M | $1.15B | · |
Balance Sheet
| Metric | Trend | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $708M | $813M | $740M | $641M | $735M | $667M | $711M | $1.72B | $4.46B | $2.35B | $1.18B | · | $923M | $1.98B | $612M | · | |
| Receivables | $2.36B | $2.21B | $2.51B | $2.99B | $2.94B | $3.03B | $2.64B | $3.03B | $2.60B | $2.56B | $2.27B | · | $2.41B | $2.41B | $2.28B | · | |
| Inventory | $3.32B | $3.36B | $4.08B | $3.89B | $3.95B | $3.72B | $3.86B | $3.84B | $3.25B | $3.23B | $3.30B | · | $3.59B | $3.66B | $3.60B | · | |
| Other Current Assets | $1.59B | $1.43B | $1.56B | $1.51B | $1.28B | $1.15B | $1.33B | $1.29B | $1.02B | $1.33B | $1.35B | · | $1.28B | $1.44B | $1.54B | · | |
| Current Assets | $8.14B | $8.01B | $9.19B | $9.26B | $9.00B | $8.67B | $8.66B | $10.47B | $12.21B | $10.34B | $8.16B | · | $8.59B | $9.59B | $8.18B | · | |
| PP&E (Net) | $6.08B | $6.08B | $6.97B | $7.00B | $6.82B | $6.65B | $6.60B | $6.82B | $6.52B | $6.59B | $6.65B | · | $6.47B | $6.36B | $6.25B | · | |
| PP&E (Gross) | $13.60B | $13.55B | $15.24B | $15.11B | $14.85B | $14.41B | $14.16B | $14.38B | $13.92B | $13.93B | $13.90B | · | $13.47B | $13.20B | $12.93B | · | |
| Accum. Depreciation | $7.52B | $7.47B | $8.27B | $8.12B | $8.04B | $7.76B | $7.55B | $7.56B | $7.40B | $7.33B | $7.25B | · | $7.00B | $6.85B | $6.68B | · | |
| Goodwill | $25.94B | $25.95B | $26.62B | $26.61B | $26.60B | $26.44B | $26.33B | $26.46B | $24.55B | $24.57B | $24.60B | $24.52B | $24.58B | $24.78B | $24.76B | $24.62B | |
| Intangibles | $8.02B | $8.35B | $9.01B | $9.39B | $9.77B | $10.12B | $10.47B | $10.87B | $9.86B | $10.21B | $10.57B | · | $11.27B | $11.63B | $11.94B | · | |
| Other Non-current Assets | $2.55B | $2.43B | $3.04B | $3.06B | $2.70B | $2.58B | $2.59B | $2.62B | $2.40B | $2.40B | $2.26B | · | $2.06B | $1.99B | $1.96B | · | |
| Total Assets | $50.73B | $50.83B | $54.84B | $55.33B | $54.90B | $54.47B | $54.66B | $57.29B | $55.58B | $54.16B | $52.27B | · | $53.02B | $54.39B | $53.13B | · | |
| Accounts Payable | $6.11B | $5.93B | $6.14B | $1.97B | $6.35B | $6.09B | $6.35B | $1.90B | $5.41B | $5.31B | $5.52B | · | $5.02B | $5.09B | $5.44B | · | |
| Accrued Liabilities | · | · | · | $3.10B | · | · | · | $3.48B | · | · | · | · | · | · | · | · | |
| Current Liabilities | $9.40B | $8.51B | $8.76B | $8.31B | $8.16B | $7.69B | $7.66B | $8.96B | $6.61B | $7.33B | $7.54B | · | $6.88B | $7.30B | $7.62B | · | |
| Capital Leases | · | · | · | $704M | · | · | · | $667M | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $2.39B | $2.46B | $2.81B | $2.93B | $2.83B | $3.00B | $3.42B | $3.56B | $4.07B | $4.30B | $4.41B | · | $4.37B | $4.47B | $4.86B | · | |
| Total Debt | $13.51B | $14.71B | $16.92B | · | $17.53B | $17.67B | $17.44B | · | $18.13B | $15.99B | $14.09B | · | $14.93B | $16.01B | $14.27B | · | |
| Common Stock | $371M | $371M | $371M | $371M | $371M | $371M | $371M | $371M | $371M | $371M | $371M | · | $371M | $365M | $365M | · | |
| Retained Earnings | $17.51B | $17.39B | $16.70B | $16.62B | $16.43B | $16.15B | $16.14B | $16.14B | $16.02B | $15.80B | $15.54B | · | $15.69B | $15.56B | $15.38B | · | |
| Treasury Stock | $12.06B | $11.66B | $10.06B | $9.81B | $9.56B | $9.56B | $9.43B | $8.81B | $8.81B | $8.81B | $8.83B | · | $8.32B | $8.33B | $8.33B | · | |
| AOCI | $-1.65B | $-1.76B | $-1.86B | $-1.90B | $-1.81B | $-1.72B | $-1.68B | $-1.73B | $-1.58B | $-1.53B | $-1.51B | · | $-1.51B | $-1.57B | $-1.56B | $-1.49B | |
| Stockholders' Equity | $24.42B | $24.13B | $25.28B | $25.39B | $25.47B | $25.24B | $25.20B | $25.89B | $25.87B | $25.65B | $25.33B | · | $25.94B | $25.69B | $25.47B | · | |
| Liabilities + Equity | $50.73B | $50.83B | $54.84B | $55.33B | $54.90B | $54.47B | $54.66B | $57.29B | $55.58B | $54.16B | $52.27B | · | $53.02B | $54.39B | $53.13B | · |
Cash Flow
| Metric | Trend | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $564M | $563M | $614M | $629M | $575M | $567M | $607M | $586M | $568M | $571M | $561M | $587M | $571M | $563M | $567M | $581M | |
| Stock-based Comp | $55M | $58M | $91M | $55M | $54M | $59M | $90M | $51M | $53M | $60M | $83M | $58M | $56M | $56M | $89M | $49M | |
| Amort. of Intangibles | $365M | $380M | $397M | $398M | $388M | $387M | $395M | $375M | $362M | $366M | $365M | $367M | $367M | $366M | $365M | $366M | |
| Restructuring | $48M | $482M | $75M | $88M | $58M | $63M | $66M | $125M | $95M | $98M | $69M | $119M | $61M | $33M | $26M | $51M | |
| Other Non-cash | · | · | $-845M | · | · | · | $-677M | · | · | · | $82M | · | · | · | $-1.43B | · | |
| Operating Cash Flow | $776M | $671M | $657M | $1.35B | $1.22B | $164M | $693M | $1.18B | $1.30B | $514M | $855M | $1.32B | $1.08B | $185M | $399M | $973M | |
| CapEx | $143M | $125M | $108M | $352M | $174M | $129M | $105M | $296M | $179M | $134M | $116M | $294M | $191M | $181M | $208M | $315M | |
| Investing Cash Flow | · | · | $-183M | $-494M | $-336M | $-192M | $204M | $-3.94B | $-288M | $-1.06B | $-233M | $137M | $-329M | $-233M | $-291M | · | |
| Net Debt Issued | $-2.00B | $-2.00B | $0 | · | · | · | $-875M | · | · | · | $0 | · | · | · | $-528M | · | |
| Stock Repurchased | $0 | $2.00B | $250M | $250M | $0 | $0 | $750M | $0 | $0 | $0 | $500M | $0 | $0 | $0 | $0 | $500M | |
| Net Stock Activity | · | · | $-250M | · | · | · | $-750M | · | · | · | $-500M | · | · | · | · | · | |
| Dividends Paid | $286M | $290M | $299M | $297M | $299M | $298M | $302M | $275M | $275M | $275M | $275M | $265M | $286M | $282M | $281M | $270M | |
| Financing Cash Flow | · | · | $-302M | $-809M | $-841M | $-39M | $-1.93B | $124M | $1.12B | $1.71B | $-862M | $-997M | $-1.79B | $1.37B | $-534M | · | |
| Net Change in Cash | $-152M | $64M | $174M | $53M | $51M | $-66M | $-1.04B | $-2.63B | $2.09B | $1.16B | $-247M | $456M | $-1.04B | $1.32B | $-415M | $-1.60B | |
| Free Cash Flow | · | · | $549M | · | · | · | $588M | · | · | · | $739M | · | · | · | $191M | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | · | $652M | · | · | · | $83M | · |
Profitability
| Metric | Trend | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 13.3% | 2.0% | 10.5% | · | 16.0% | 10.4% | 8.8% | · | 12.1% | 14.5% | 9.3% | · | 11.2% | 13.0% | 12.8% | · | |
| Net Margin | 7.6% | -6.6% | 7.3% | · | 10.4% | 5.8% | 5.9% | · | 9.8% | 10.6% | 6.0% | · | 8.3% | 9.5% | 11.1% | · | |
| Pretax Margin | 11.1% | 0.83% | 7.5% | · | 12.8% | 6.9% | 5.9% | · | 10.0% | 12.6% | 7.6% | · | 9.7% | 11.0% | 10.5% | · | |
| EBITDA Margin | 24.6% | 13.9% | 22.2% | · | 16.0% | 10.4% | 20.5% | · | 12.1% | 14.5% | 21.2% | · | 11.2% | 13.0% | 25.1% | · | |
| ROA | 0.71% | -0.59% | 0.70% | · | 1.0% | 0.57% | 0.57% | · | 0.90% | 0.99% | 0.53% | · | 0.77% | 0.84% | 0.96% | · | |
| ROE | 1.5% | -1.3% | 1.5% | · | 2.2% | 1.2% | 1.2% | · | 1.9% | 2.1% | 1.1% | · | 1.6% | 1.8% | 2.1% | · | |
| ROIC | 1.4% | -0.23% | 1.3% | · | 1.7% | 1.1% | 1.1% | · | 1.3% | 1.5% | 0.87% | · | 1.2% | 1.3% | 1.6% | · |
Liquidity & Solvency
| Metric | Trend | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.9 | 0.9 | 1.0 | · | 1.1 | 1.1 | 1.1 | · | 1.8 | 1.4 | 1.1 | · | 1.2 | 1.3 | 1.1 | · | |
| Quick Ratio | 0.3 | 0.4 | 0.4 | · | 0.5 | 0.5 | 0.4 | · | 1.1 | 0.7 | 0.5 | · | 0.5 | 0.6 | 0.4 | · | |
| Debt / Equity | 0.6 | 0.6 | 0.7 | · | 0.7 | 0.7 | 0.7 | · | 0.7 | 0.6 | 0.6 | · | 0.6 | 0.6 | 0.6 | · | |
| LT Debt / Equity | 0.6 | 0.6 | 0.7 | · | 0.7 | 0.7 | 0.7 | · | 0.7 | 0.6 | 0.6 | · | 0.6 | 0.6 | 0.6 | · | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | 5.9 | 4.0 | · | 4.6 | 5.3 | 5.7 | · |
Efficiency
| Metric | Trend | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | |
| Inventory Turnover | 0.7 | 0.7 | 0.7 | · | 0.8 | 0.9 | 0.8 | · | 0.8 | 0.8 | 0.8 | · | 0.8 | 0.7 | 0.7 | · | |
| Receivables Turnover | 1.9 | 1.8 | 2.0 | · | 2.0 | 1.9 | 2.1 | · | 2.0 | 2.0 | 2.1 | · | 2.1 | 2.0 | 2.1 | · |
Per Share
| Metric | Trend | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue / Share | $18.11 | $16.80 | $18.37 | · | $19.18 | $18.32 | $17.80 | · | $17.19 | $17.38 | $16.15 | · | $16.94 | $16.88 | $16.07 | · | |
| Cash Flow / Share | · | · | $2.30 | · | · | · | $2.39 | · | · | · | $2.93 | · | · | · | $1.40 | · | |
| Dividend / Share | $1.05 | $1.05 | $1.05 | · | $1.04 | $1.04 | $1.04 | · | $0.95 | $0.95 | $0.95 | · | $0.91 | $0.91 | $0.91 | · | |
| EPS (TTM) | $3.31 | $3.94 | $6.12 | · | $5.48 | $5.16 | $5.94 | · | $4.84 | $4.52 | $4.20 | · | $5.51 | $5.33 | $5.30 | · |
Valuation (TTM)
| Metric | Trend | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $20.84B | $20.58B | $20.35B | · | $19.81B | $20.07B | $20.64B | · | $19.83B | $19.72B | $19.49B | · | $19.05B | $18.81B | $18.74B | · | |
| Net Income TTM | $941M | $1.14B | $1.76B | · | $1.58B | $1.50B | $1.73B | · | $1.41B | $1.33B | $1.26B | · | $1.66B | $1.62B | $1.61B | · | |
| P/E | 45.7 | 39.9 | 24.9 | · | 24.7 | 34.9 | 30.0 | · | 38.0 | 43.0 | 45.6 | · | 37.7 | 36.5 | 37.7 | · | |
| Earnings Yield | 2.2% | 2.5% | 4.0% | · | 4.0% | 2.9% | 3.3% | · | 2.6% | 2.3% | 2.2% | · | 2.6% | 2.7% | 2.6% | · | |
| Payout Ratio | · | · | 78.3% | · | · | · | 99.7% | · | · | · | 97.9% | · | · | · | 55.2% | · | |
| Annual Payout | $1.17B | $1.19B | $1.19B | · | $1.17B | $1.15B | $1.13B | · | $1.09B | $1.10B | $1.11B | · | $1.12B | $1.10B | $1.09B | · |
Most recent period on the left · null values shown as ·
Financial Statements Income statement, balance sheet, cash flow — annual, last 5 years
| Metric | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Revenue | $21.84B | $20.18B | $19.37B | $18.87B | $19.13B |
| Operating Margin % | 11.8% | 11.9% | 10.9% | 12.1% | 13.8% |
| Net Income | $1.68B | $1.71B | $1.48B | $1.78B | $2.09B |
| Diluted EPS | $5.82 | $5.86 | $4.94 | $5.88 | $6.85 |
| Metric | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Debt / Equity | 0.7 | 0.7 | 0.6 | 0.5 | 0.7 |
| Current Ratio | 1.1 | 1.2 | 1.3 | 1.0 | 1.3 |
| Quick Ratio | 0.4 | 0.5 | 0.6 | 0.4 | 0.7 |
| Metric | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|
| Free Cash Flow | $2.67B | $3.12B | $2.12B | $1.50B | $3.42B |
Institutional owners (13F) 1,564 filers · $47.0B total · As of Sept. 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Holders
1,564
Value held
$47.0B
New positions
127
Exited positions
143
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 127 (-29 vs prior Q) | 143 (-44 vs prior Q) | 551 (-15 vs prior Q) | 552 (+16 vs prior Q) | +10.1M |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| VANGUARD GROUP INC | $7,118,281,692 | 36,678,939 | 15.14% | Shares |
| BlackRock, Inc. | $3,721,532,551 | 24,592,166 | 7.92% | Shares |
| VANGUARD CAPITAL MANAGEMENT LLC | $2,722,098,919 | 17,987,834 | 5.79% | Shares |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | $2,483,123,897 | 8,650,967 | 5.28% | Shares |
| STATE STREET CORP | $2,269,959,685 | 15,000,064 | 4.83% | Shares |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $2,266,036,001 | 14,974,136 | 4.82% | Shares |
| First Eagle Investment Management, LLC | $2,090,674,677 | 13,815,335 | 4.45% | Shares |
| Invesco Ltd. | $1,346,608,236 | 8,898,488 | 2.86% | Shares |
| GEODE CAPITAL MANAGEMENT, LLC | $1,228,361,034 | 8,141,586 | 2.61% | Shares |
| FRANKLIN RESOURCES INC | $1,061,064,151 | 7,011,592 | 2.26% | Shares |
| WELLINGTON MANAGEMENT GROUP LLP | $962,154,023 | 6,357,986 | 2.05% | Shares |
| GREENHAVEN ASSOCIATES INC | $859,812,872 | 5,681,708 | 1.83% | Shares |
| NORGES BANK | $630,973,916 | 4,169,523 | 1.34% | Shares |
| AMERICAN CENTURY COMPANIES INC | $556,370,023 | 3,676,534 | 1.18% | Shares |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $515,287,516 | 3,398,203 | 1.10% | Shares |
| MORGAN STANLEY | $502,353,875 | 3,319,590 | 1.07% | Shares |
| Clearbridge Investments, LLC | $489,222,504 | 3,232,819 | 1.04% | Shares |
| BANK OF AMERICA CORP /DE/ | $474,992,547 | 3,138,786 | 1.01% | Shares |
| JPMORGAN CHASE & CO | $440,071,112 | 2,835,692 | 0.94% | Shares |
| NORTHERN TRUST CORP | $397,274,543 | 2,625,220 | 0.85% | Shares |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $385,001,377 | 2,544,118 | 0.82% | Shares |
| HARRIS ASSOCIATES L P | $355,771,231 | 2,350,963 | 0.76% | Shares |
| DIMENSIONAL FUND ADVISORS LP | $324,096,377 | 2,141,003 | 0.69% | Shares |
| First Pacific Advisors, LP | $319,426,456 | 2,110,794 | 0.68% | Shares |
| Legal & General Group Plc | $318,049,508 | 2,101,695 | 0.68% | Shares |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $296,900,554 | 1,888,320 | 0.63% | Shares |
| Amundi | $274,921,665 | 1,816,703 | 0.58% | Shares |
| GOLDMAN SACHS GROUP INC | $266,177,531 | 1,758,921 | 0.57% | Shares |
| Longview Partners (Guernsey) LTD | $255,761,774 | 1,690,093 | 0.54% | Shares |
| BRANDES INVESTMENT PARTNERS, LP | $252,955,949 | 1,671,540 | 0.54% | Shares |
| Bank of New York Mellon Corp | $247,371,528 | 1,634,649 | 0.53% | Shares |
| VANGUARD FIDUCIARY TRUST CO | $234,270,795 | 1,548,079 | 0.50% | Shares |
| MACKENZIE FINANCIAL CORP | $216,917,330 | 1,433,406 | 0.46% | Shares |
| Veritas Asset Management LLP | $210,852,478 | 1,393,329 | 0.45% | Shares |
| DEUTSCHE BANK AG\ | $204,226,494 | 1,349,544 | 0.43% | Shares |
| FORT WASHINGTON INVESTMENT ADVISORS INC /OH/ | $199,143,586 | 1,112,534 | 0.42% | Shares |
| BARCLAYS PLC | $191,750,849 | 1,267,104 | 0.41% | Shares |
| UBS Group AG | $183,686,019 | 1,213,811 | 0.39% | Shares |
| WELLS FARGO & COMPANY/MN | $183,226,555 | 1,210,775 | 0.39% | Shares |
| JARISLOWSKY, FRASER Ltd | $175,028,282 | 935,130 | 0.37% | Shares |
| ProShare Advisors LLC | $162,283,113 | 1,072,379 | 0.35% | Shares |
| ENVESTNET ASSET MANAGEMENT INC | $156,784,054 | 1,036,041 | 0.33% | Shares |
| COOKE & BIELER LP | $152,946,908 | 854,452 | 0.33% | Shares |
| RAYMOND JAMES FINANCIAL INC | $152,018,930 | 1,004,552 | 0.32% | Shares |
| Focus Partners Wealth | $144,422,511 | 954,318 | 0.31% | Shares |
| Findlay Park Partners LLP | $143,945,096 | 951,200 | 0.31% | Shares |
| M&G PLC | $134,044,663 | 887,713 | 0.29% | Shares |
| FIDUCIARY MANAGEMENT INC /WI/ | $125,873,419 | 831,781 | 0.27% | Shares |
| Cullen Capital Management, LLC | $124,804,866 | 824,720 | 0.27% | Shares |
| Swiss National Bank | $121,639,357 | 803,802 | 0.26% | Shares |
Activists & 5%+ owners 5 positions
Investors who filed SEC Schedule 13D — beneficial ownership above 5% with an intent to influence the issuer (activist stakes, board campaigns, M&A). Each row shows the most recent known state of that filer's position.
| Filer | Filed | Stake | Status | Purpose | Filing |
|---|---|---|---|---|---|
| Undisclosed reporting person | Sept. 8, 2006 | · | Initial filing | · | SEC |
| Undisclosed reporting person | Sept. 1, 2006 | · | Initial filing | · | SEC |
| Undisclosed reporting person | Aug. 25, 2006 | · | Initial filing | · | SEC |
| Undisclosed reporting person | Aug. 16, 2006 | · | Initial filing | · | SEC |
| Undisclosed reporting person | Aug. 14, 2006 | · | Initial filing | Passive investment | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Company insiders 83 insiders · 47 officers · 27 directors
| Insider | Role | Last activity | Shares owned | Buys 12m | Sells 12m | Net 12m |
|---|---|---|---|---|---|---|
| Thomas E Polen Jr | Chairman, CEO and President | Aug. 13, 2026 M | 110,163 | 0 | 2 | $-1,172,631 |
| Vitor Roque | EVP & Chief Financial Officer | Sept. 2, 2026 F | 8,041 | 0 | 0 | $0 |
| Christopher Delorefice | EVP & Chief Financial Officer | Nov. 26, 2025 F | 22,982 | 0 | 0 | $0 |
| Christopher R Reidy | CFO and EVP of Administration | Nov. 26, 2021 A | 31,524 | 0 | 0 | $0 |
| David V Elkins | Executive VP and CFO | Nov. 9, 2012 D | 0 | 0 | 0 | $0 |
| Michael Feld | EVP, Chief Revenue Officer | Sept. 28, 2026 S | 19,644 | 0 | 12 | $-170,822 |
| Roland Goette | EVP and President, EMEA | Aug. 11, 2026 S | 14,856 | 0 | 1 | $-440,888 |
| Bilal Muhsin | EVP & President Connected Care | July 2, 2026 F | 41,359 | 0 | 0 | $0 |
| Michael David Garrison | EVP & Pres Med.Essntl&BioPharm | June 24, 2026 S | 13,172 | 0 | 5 | $-784,162 |
| Peter Menziuso | EVP and President, BDI | June 1, 2026 A | 14,258 | 0 | 0 | $0 |
| Shana Carol Neal | EVP and Chief People Officer | April 6, 2026 F | 23,966 | 0 | 0 | $0 |
| Lanesha Minnix | EVP and General Counsel | March 16, 2026 A | 7,492 | 0 | 0 | $0 |
| Pamela L. Spikner | SVP Controller & CAO | March 2, 2026 A | 3,323 | 0 | 0 | $0 |
| David Shan | EVP and Chief ISC Officer | Jan. 3, 2026 F | 8,926 | 0 | 0 | $0 |
| Richard Byrd | EVP & President Interventional | Nov. 26, 2025 F | 13,849 | 0 | 0 | $0 |
| Pavan Kumar Mocherla | EVP & President, Greater Asia | Nov. 26, 2025 A | 5,763 | 0 | 0 | $0 |
| Michelle Quinn | EVP and General Counsel | Nov. 26, 2024 A | 6,927 | 0 | 0 | $0 |
| Antoine C Ezell | EVP, President Americas & CMO | Nov. 26, 2024 A | 11,970 | 0 | 0 | $0 |
| Thomas J Spoerel | SVPController & Chief Acct Off | July 1, 2024 F | 1,928 | 0 | 0 | $0 |
| David Hickey | EVP & President, Life Sciences | Nov. 26, 2023 A | 5,862 | 0 | 0 | $0 |
| Samrat S. Khichi | EVP and General Counsel | Dec. 21, 2022 G | 9,251 | 0 | 0 | $0 |
| Rishi Grover | EVP and Chief ISC Officer | July 8, 2022 A | 9,439 | 0 | 0 | $0 |
| James Lim | Executive Vice President | June 17, 2022 A | 23,941 | 0 | 0 | $0 |
| Betty D Larson | EVP HR & CHRO | Feb. 25, 2022 M | 5,872 | 0 | 0 | $0 |
| Simon D Campion | EVP and Segment President | Feb. 11, 2022 G | 10,319 | 0 | 0 | $0 |
| Alexandre Conroy | EVP of Integrated Supply Chain | Feb. 3, 2022 M | 21,260 | 0 | 0 | $0 |
| Ribo Alberto Mas | EVP and Pres, Life Sciences | Nov. 26, 2021 A | 11,662 | 0 | 0 | $0 |
| Vincent A Forlenza | Chairman of the Board | Dec. 15, 2020 G | 194,048 | 0 | 0 | $0 |
| Patrick Kaltenbach | EVP & Pres Life Sciences | Nov. 26, 2020 A | 10,340 | 0 | 0 | $0 |
| Charles R Bodner | SVP Corp Fin Chief Acct Office | Sept. 6, 2019 M | 2,037 | 0 | 0 | $0 |
| James W Borzi | EVP & Chief Supply Chain Offcr | Nov. 30, 2018 M | 2,775 | 0 | 0 | $0 |
| William A Tozzi | EVP Pres Interventional | July 2, 2018 A | 12,830 | 0 | 0 | $0 |
| Nabil Shabshab | Executive Vice President | May 11, 2018 M | 7,811 | 0 | 0 | $0 |
| John E Gallagher | VP, Corp Finance and Treasurer | March 2, 2018 F | 1,975 | 0 | 0 | $0 |
| Linda M Tharby | Executive Vice President | Feb. 1, 2018 M | 13,437 | 0 | 0 | $0 |
| John P Groetelaars | EVP | Jan. 2, 2018 A | 42,508 | 0 | 0 | $0 |
| Ellen R Strahlman | Senior Vice President | Nov. 25, 2017 F | 6,898 | 0 | 0 | $0 |
| Gary M Cohen | Executive Vice President | Sept. 11, 2017 M | 71,770 | 0 | 0 | $0 |
| Stephen Sichak | Executive Vice President | Sept. 8, 2017 M | 7,953 | 0 | 0 | $0 |
| Jeffrey S Sherman | Sr. VP and General Counsel | May 25, 2017 M | 22,094 | 0 | 0 | $0 |
| Jerome V Hurwitz | Executive Vice President | May 6, 2016 S | 3,027 | 0 | 0 | $0 |
| William A Kozy | Executive Vice President | Dec. 9, 2015 S | 68,823 | 0 | 0 | $0 |
| Joseph Mercurio | VP and Corporate Controller | Nov. 25, 2014 A | 1,932 | 0 | 0 | $0 |
| Donna M Boles | Senior VP - Human Resources | May 17, 2013 M | 14,607 | 0 | 0 | $0 |
| Suketu Upadhyay | Senior VP and Controller | Nov. 20, 2012 A | 3,525 | 0 | 0 | $0 |
| William E. Rhodes | Senior Vice President | Nov. 20, 2012 A | 5,972 | 0 | 0 | $0 |
| Edward J Ludwig | Chairman | March 20, 2012 G | 95,188 | 0 | 0 | $0 |
| Carrie L Byington | Director | Aug. 6, 2026 A | 5,018 | 0 | 0 | $0 |
| Robert Luther Huffines | Director | Aug. 6, 2026 A | 1,279 | 0 | 0 | $0 |
| Bertram L Scott | Director | Feb. 18, 2026 S | 36,763 | 0 | 2 | $-212,345 |
| Christopher Ian Montague Jones | Director | Feb. 4, 2026 A | 24,304 | 0 | 0 | $0 |
| Joanne Waldstreicher | Director | Jan. 27, 2026 A | 3,391 | 0 | 0 | $0 |
| Jacqueline Wright | Director | Jan. 27, 2026 A | 1,279 | 0 | 0 | $0 |
| William M Brown | Director | Jan. 27, 2026 A | 4,663 | 0 | 0 | $0 |
| Jeffrey William Henderson | Director | Jan. 27, 2026 A | 9,143 | 0 | 0 | $0 |
| Gregory Hayes | Director | Jan. 27, 2026 A | 7,159 | 0 | 0 | $0 |
| Andrew R Eckert | Director | Jan. 27, 2026 A | 10,423 | 0 | 0 | $0 |
| Timothy M Ring | Director | Jan. 27, 2026 A | 59,160 | 0 | 0 | $0 |
| Catherine M Burzik | Director | Jan. 28, 2025 A | 14,264 | 0 | 0 | $0 |
| LARSEN MARSHALL O | Director | Jan. 24, 2023 A | 28,919 | 0 | 0 | $0 |
| Claire Pomeroy | Director | Jan. 25, 2022 A | 9,982 | 0 | 0 | $0 |
| David F Melcher | Director | Jan. 25, 2022 A | 6,180 | 0 | 0 | $0 |
| Rebecca W Rimel | Director | Sept. 8, 2021 S | 10,618 | 0 | 0 | $0 |
| Gary A Mecklenburg | Director | Nov. 6, 2018 A | 25,453 | 0 | 0 | $0 |
| Wilard J Overlock JR | Director | Nov. 6, 2018 A | 19,442 | 0 | 0 | $0 |
| James F Orr | Director | Jan. 24, 2017 A | 24,257 | 0 | 0 | $0 |
| Basil Anderson | Director | Jan. 26, 2016 A | 22,596 | 0 | 0 | $0 |
| Henry P Becton JR | Director | Nov. 3, 2015 A | 112,683 | 0 | 0 | $0 |
| Edward Degraan | Director | Jan. 27, 2015 A | 22,416 | 0 | 0 | $0 |
| Alfred Sommer | Director | Jan. 28, 2014 A | 20,689 | 0 | 0 | $0 |
| Adel Mahmoud | Director | Jan. 29, 2013 A | 13,746 | 0 | 0 | $0 |
| Claire Fraser | · | Sept. 10, 2025 S | 22,226 | 0 | 0 | $0 |
| David T Durack | · | April 28, 2011 M | 8,908 | 0 | 0 | $0 |
| Cathy E. Minehan | · | Feb. 1, 2011 A | 8,535 | 0 | 0 | $0 |
| Scott P Bruder | · | Nov. 23, 2010 A | 7,626 | 0 | 0 | $0 |
| Patricia B Shrader | · | Nov. 23, 2010 A | 11,250 | 0 | 0 | $0 |
| John R Considine | · | Nov. 24, 2009 A | 93,438 | 0 | 0 | $0 |
| Alfred John Hanson | · | Nov. 25, 2008 A | 46,146 | 0 | 0 | $0 |
| James E Perrella | · | Oct. 31, 2007 A | 18,520 | 0 | 0 | $0 |
| Margeretha Af Ugglas | · | Jan. 31, 2007 A | 15,920 | 0 | 0 | $0 |
| Jean Marc Dageville | · | Dec. 8, 2004 M | 4,658 | 0 | 0 | $0 |
| Harry N Beaty | · | May 3, 2004 M | 9,204 | 0 | 0 | $0 |
| OLSON FRANK ALBERT | · | Feb. 11, 2004 A | 21,200 | 0 | 0 | $0 |
Insiders from SEC Form 3/4/5 filings; net = open-market P/S only
ETF ownership Held by 154 ETFs
Weight reflects direct equity holdings (N-PORT) only; leveraged or derivative-based funds may hold additional swap exposure not shown.
| Fund | Weight | Units | As of | Source |
|---|---|---|---|---|
| IHI · iShares Trust | 5.24% | 943,719 SH | Sept. 11, 2026 | Daily |
| EQTY · Valued Advisers Trust | 2.14% | 184,537 NS | July 31, 2026 | N-PORT |
| UPGD · Invesco Exchange-Traded Fund Trust | 2.11% | 11,886 SH | Oct. 23, 2026 | Daily |
| BMVP · Invesco Exchange-Traded Fund Trust | 1.92% | 10,099 SH | Oct. 23, 2026 | Daily |
| RSPH · Invesco Exchange-Traded Fund Trust | 1.70% | 81,936 SH | Oct. 23, 2026 | Daily |
| EPOL · iShares Trust | 1.60% | 69,343 SH | Sept. 11, 2026 | Daily |
| FXH · First Trust Exchange-Traded AlphaDE… | 1.49% | 94,088 NS | July 31, 2026 | N-PORT |
| KNG · First Trust Exchange-Traded Fund IV | 1.49% | 317,073 NS | July 31, 2026 | N-PORT |
| COWZ · Pacer Funds Trust | 1.01% | 1,134,820 NS | July 31, 2026 | N-PORT |
| IYH · iShares Trust | 0.81% | 166,236 SH | Sept. 11, 2026 | Daily |
| RGEF · Tidal Trust III | 0.73% | 35,725 NS | July 31, 2026 | N-PORT |
| VOE · VANGUARD INDEX FUNDS | 0.72% | 1,769,988 SH | Aug. 19, 2026 | Daily |
| SNPD · DBX ETF Trust | 0.72% | 117 NS | Aug. 31, 2026 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0.68% | 135,578 NS | July 31, 2026 | N-PORT |
| IMCV · iShares Trust | 0.68% | 44,851 SH | Sept. 11, 2026 | Daily |
| REVS · Columbia ETF Trust I | 0.65% | 13,100 NS | July 31, 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0.64% | 856,811 SH | Aug. 19, 2026 | Daily |
| ACVU · Hartford Funds Exchange-Traded Trust | 0.62% | 6,797 NS | July 31, 2026 | N-PORT |
| IXJ · iShares Trust | 0.62% | 144,713 SH | Sept. 11, 2026 | Daily |
| CURE · Direxion Shares ETF Trust | 0.52% | 5,422 NS | July 31, 2026 | N-PORT |
| IWS · iShares Trust | 0.49% | 424,696 SH | Sept. 11, 2026 | Daily |
| EQIN · Columbia ETF Trust I | 0.48% | 8,836 NS | July 31, 2026 | N-PORT |
| RECS · Columbia ETF Trust I | 0.42% | 148,656 NS | July 31, 2026 | N-PORT |
| FDLO · FIDELITY COVINGTON TRUST | 0.41% | 35,456 NS | July 31, 2026 | N-PORT |
| DIVB · iShares Trust | 0.40% | 46,677 SH | Sept. 11, 2026 | Daily |
| VO · VANGUARD INDEX FUNDS | 0.40% | 5,971,067 SH | Aug. 19, 2026 | Daily |
| BSCR · Invesco Exchange-Traded Self-Indexe… | 0.40% | 17,920,000 | Oct. 23, 2026 | Daily |
| HUSV · First Trust Exchange-Traded Fund III | 0.38% | 1,706 NS | July 31, 2026 | N-PORT |
| FTA · First Trust Exchange-Traded AlphaDE… | 0.38% | 31,777 NS | July 31, 2026 | N-PORT |
| VFMV · VANGUARD WELLINGTON FUND | 0.37% | 10,309 SH | Aug. 19, 2026 | Daily |
| IWR · iShares Trust | 0.37% | 1,164,966 SH | Sept. 11, 2026 | Daily |
| VLUE · iShares Trust | 0.36% | 194,404 SH | Sept. 11, 2026 | Daily |
| JPME · J.P. Morgan Exchange-Traded Fund Tr… | 0.35% | 9,750 NS | July 31, 2026 | N-PORT |
| IMCB · iShares Trust | 0.34% | 32,267 SH | Sept. 11, 2026 | Daily |
| JPUS · J.P. Morgan Exchange-Traded Fund Tr… | 0.34% | 9,256 NS | July 31, 2026 | N-PORT |
| VFVA · VANGUARD WELLINGTON FUND | 0.33% | 18,654 SH | Aug. 19, 2026 | Daily |
| FEX · First Trust Exchange-Traded AlphaDE… | 0.30% | 27,935 NS | July 31, 2026 | N-PORT |
| DGRO · iShares Trust | 0.29% | 717,789 SH | Sept. 11, 2026 | Daily |
| DEUS · DBX ETF Trust | 0.29% | 4,659 NS | Aug. 31, 2026 | N-PORT |
| XOEF · iShares Trust | 0.27% | 347 SH | Sept. 11, 2026 | Daily |
| DFLV · Dimensional ETF Trust | 0.26% | 104,844 NS | July 31, 2026 | N-PORT |
| SIZE · iShares Trust | 0.23% | 5,494 SH | Sept. 11, 2026 | Daily |
| RSP · Invesco Exchange-Traded Fund Trust | 0.22% | 1,091,618 SH | Oct. 23, 2026 | Daily |
| IUS · Invesco Exchange-Traded Self-Indexe… | 0.22% | 10,973 SH | Oct. 23, 2026 | Daily |
| PFM · Invesco Exchange-Traded Fund Trust | 0.19% | 7,710 SH | Oct. 23, 2026 | Daily |
| EUSA · iShares, Inc. | 0.19% | 20,800 SH | Sept. 11, 2026 | Daily |
| FAB · First Trust Exchange-Traded AlphaDE… | 0.19% | 1,919 NS | July 31, 2026 | N-PORT |
| BSCU · Invesco Exchange-Traded Self-Indexe… | 0.19% | 5,677,000 | Oct. 23, 2026 | Daily |
| DFUV · Dimensional ETF Trust | 0.18% | 171,825 NS | July 31, 2026 | N-PORT |
| PFIG · Invesco Exchange-Traded Fund Trust … | 0.18% | 255,000 | Oct. 23, 2026 | Daily |
| BSCS · Invesco Exchange-Traded Self-Indexe… | 0.18% | 6,442,000 | Oct. 20, 2026 | Daily |
| VIG · VANGUARD SPECIALIZED FUNDS | 0.18% | 1,556,657 SH | Aug. 19, 2026 | Daily |
| VYM · VANGUARD WHITEHALL FUNDS | 0.18% | 1,134,690 SH | Aug. 19, 2026 | Daily |
| FEUS · FlexShares Trust | 0.17% | 1,155 NS | July 31, 2026 | N-PORT |
| MNZL · EA Series Trust | 0.17% | 252 NS | July 31, 2026 | N-PORT |
| IVE · iShares Trust | 0.16% | 457,195 SH | Sept. 11, 2026 | Daily |
| VTV · VANGUARD INDEX FUNDS | 0.16% | 2,617,912 SH | Aug. 19, 2026 | Daily |
| IUSV · iShares Trust | 0.15% | 240,462 SH | Sept. 11, 2026 | Daily |
| BSCT · Invesco Exchange-Traded Self-Indexe… | 0.14% | 4,447,000 | Oct. 23, 2026 | Daily |
| ILCV · iShares Trust | 0.14% | 10,712 SH | Sept. 11, 2026 | Daily |
| VOOV · VANGUARD ADMIRAL FUNDS | 0.14% | 63,464 SH | Aug. 19, 2026 | Daily |
| EMGF · iShares, Inc. | 0.14% | 14,306 SH | Sept. 10, 2026 | Daily |
| DSI · iShares Trust | 0.14% | 42,114 SH | Sept. 11, 2026 | Daily |
| PRF · Invesco Exchange-Traded Fund Trust | 0.14% | 68,990 SH | Oct. 23, 2026 | Daily |
| IWD · iShares Trust | 0.14% | 632,304 SH | Sept. 11, 2026 | Daily |
| SNPE · DBX ETF Trust | 0.13% | 19,771 NS | Aug. 31, 2026 | N-PORT |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0.12% | 171,632 SH | Aug. 19, 2026 | Daily |
| GLBL · Pacer Funds Trust | 0.12% | 8 NS | July 31, 2026 | N-PORT |
| SPXD · DBX ETF Trust | 0.12% | 45 NS | Aug. 31, 2026 | N-PORT |
| DFVX · Dimensional ETF Trust | 0.12% | 3,749 NS | July 31, 2026 | N-PORT |
| RWL · Invesco Exchange-Traded Fund Trust … | 0.11% | 59,005 SH | Oct. 23, 2026 | Daily |
| QVML · Invesco Exchange-Traded Fund Trust … | 0.11% | 9,553 SH | Oct. 23, 2026 | Daily |
| ESG · FlexShares Trust | 0.11% | 840 NS | July 31, 2026 | N-PORT |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0.11% | 4,269 SH | Oct. 23, 2026 | Daily |
| HDUS · Lattice Strategies Trust | 0.10% | 1,192 NS | July 31, 2026 | N-PORT |
| TOPC · iShares Trust | 0.09% | 171 SH | Sept. 11, 2026 | Daily |
| ACVF · ETF Opportunities Trust | 0.09% | 795 NS | July 31, 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0.08% | 244,485 NS | July 31, 2026 | N-PORT |
| PBUS · Invesco Exchange-Traded Fund Trust … | 0.08% | 44,129 SH | Oct. 23, 2026 | Daily |
| PBP · Invesco Exchange-Traded Fund Trust | 0.08% | 1,634 SH | Oct. 23, 2026 | Daily |
| XVV · iShares Trust | 0.08% | 3,163 SH | Sept. 11, 2026 | Daily |
| IVV · iShares Trust | 0.07% | 3,473,127 SH | Sept. 11, 2026 | Daily |
| CRBN · iShares Trust | 0.07% | 4,897 SH | Sept. 11, 2026 | Daily |
| ILCB · iShares Trust | 0.07% | 5,340 SH | Sept. 11, 2026 | Daily |
| BKLC · BNY Mellon ETF Trust | 0.07% | 24,016 NS | July 31, 2026 | N-PORT |
| IWB · iShares Trust | 0.07% | 197,581 SH | Sept. 11, 2026 | Daily |
| BBUS · J.P. Morgan Exchange-Traded Fund Tr… | 0.07% | 38,024 NS | July 31, 2026 | N-PORT |
| PTLC · Pacer Funds Trust | 0.07% | 13,955 NS | July 31, 2026 | N-PORT |
| DFAU · Dimensional ETF Trust | 0.07% | 53,117 NS | July 31, 2026 | N-PORT |
| VOTE · TCW ETF Trust | 0.07% | 4,662 NS | July 31, 2026 | N-PORT |
| VV · VANGUARD INDEX FUNDS | 0.07% | 321,801 SH | Aug. 19, 2026 | Daily |
| ESGV · VANGUARD WORLD FUND | 0.07% | 64,270 SH | Aug. 19, 2026 | Daily |
| TOV · EA Series Trust | 0.07% | 1,117 NS | July 31, 2026 | N-PORT |
| PHDG · Invesco Actively Managed Exchange-T… | 0.07% | 215 SH | Oct. 23, 2026 | Daily |
| IYY · iShares Trust | 0.07% | 11,794 SH | Sept. 11, 2026 | Daily |
| DXUV · Dimensional ETF Trust | 0.07% | 2,283 NS | July 31, 2026 | N-PORT |
| VOXP · Advisors Series Trust | 0.07% | 24 NS | July 31, 2026 | N-PORT |
| IWV · iShares Trust | 0.07% | 78,106 SH | Sept. 11, 2026 | Daily |
| USCL · iShares Trust | 0.07% | 10,939 SH | Sept. 11, 2026 | Daily |
| ITOT · iShares Trust | 0.07% | 359,241 SH | Sept. 11, 2026 | Daily |
| DFUS · Dimensional ETF Trust | 0.07% | 83,341 NS | July 31, 2026 | N-PORT |
| SPUU · Direxion Shares ETF Trust | 0.07% | 1,039 NS | July 31, 2026 | N-PORT |
| QDPL · Pacer Funds Trust | 0.06% | 6,630 NS | July 31, 2026 | N-PORT |
| LRGF · iShares Trust | 0.06% | 13,430 SH | Sept. 11, 2026 | Daily |
| KOKU · DBX ETF Trust | 0.06% | 2,685 NS | Aug. 31, 2026 | N-PORT |
| VOO · VANGUARD INDEX FUNDS | 0.06% | 7,153,108 SH | Aug. 19, 2026 | Daily |
| VTI · VANGUARD INDEX FUNDS | 0.06% | 8,748,767 SH | Aug. 19, 2026 | Daily |
| VSS · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.06% | 47,858 SH | Aug. 19, 2026 | Daily |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0.06% | 47,190 SH | Aug. 19, 2026 | Daily |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.06% | 23,933 SH | Aug. 19, 2026 | Daily |
| TOK · iShares Trust | 0.06% | 795 SH | Sept. 11, 2026 | Daily |
| DCOR · Dimensional ETF Trust | 0.06% | 11,787 NS | July 31, 2026 | N-PORT |
| HCMT · Direxion Shares ETF Trust | 0.06% | 1,923 NS | July 31, 2026 | N-PORT |
| URTH · iShares, Inc. | 0.06% | 25,569 SH | Sept. 11, 2026 | Daily |
| JFLI · J.P. Morgan Exchange-Traded Fund Tr… | 0.05% | 156 NS | July 31, 2026 | N-PORT |
| QARP · DBX ETF Trust | 0.05% | 222 NS | Aug. 31, 2026 | N-PORT |
| SPXL · Direxion Shares ETF Trust | 0.05% | 21,539 NS | July 31, 2026 | N-PORT |
| TILT · FlexShares Trust | 0.05% | 6,952 NS | July 31, 2026 | N-PORT |
| LDEM · iShares Trust | 0.05% | 91 SH | Sept. 11, 2026 | Daily |
| ACWI · iShares Trust | 0.05% | 94,438 SH | Sept. 11, 2026 | Daily |
| DFSU · Dimensional ETF Trust | 0.05% | 6,917 NS | July 31, 2026 | N-PORT |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0.05% | 11,455 SH | Oct. 23, 2026 | Daily |
| APUE · Trust for Professional Managers | 0.05% | 6,347 NS | Aug. 31, 2026 | N-PORT |
| EMXF · iShares Trust | 0.04% | 384 SH | Sept. 11, 2026 | Daily |
| PDN · Invesco Exchange-Traded Fund Trust … | 0.04% | 796 SH | Oct. 23, 2026 | Daily |
| ROUS · Lattice Strategies Trust | 0.04% | 1,753 NS | July 31, 2026 | N-PORT |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.04% | 247,589 SH | Aug. 19, 2026 | Daily |
| GLOF · iShares Trust | 0.04% | 380 SH | Sept. 11, 2026 | Daily |
| JVAL · J.P. Morgan Exchange-Traded Fund Tr… | 0.04% | 1,792 NS | July 31, 2026 | N-PORT |
| EMXC · iShares, Inc. | 0.02% | 33,336 SH | Sept. 11, 2026 | Daily |
| VGK · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.02% | 30,768 SH | Aug. 19, 2026 | Daily |
| EEM · iShares, Inc. | 0.02% | 31,606 SH | Sept. 10, 2026 | Daily |
| IEMG · iShares, Inc. | 0.02% | 152,904 SH | Sept. 10, 2026 | Daily |
| LGDX · Tidal Trust III | 0.01% | 113 NS | July 31, 2026 | N-PORT |
| VXUS · VANGUARD STAR FUNDS | 0.01% | 186,147 SH | Aug. 19, 2026 | Daily |
| VEA · VANGUARD TAX-MANAGED FUNDS | 0.01% | 125,091 SH | Aug. 19, 2026 | Daily |
| VSGX · VANGUARD WORLD FUND | 0.01% | 2,529 SH | Aug. 19, 2026 | Daily |
| AQLT · iShares Trust | 0.01% | 158 SH | Sept. 10, 2026 | Daily |
| PEVC · Pacer Funds Trust | 0.01% | 1 NS | July 31, 2026 | N-PORT |
| ACWX · iShares Trust | 0.01% | 3,911 SH | Sept. 10, 2026 | Daily |
| IXUS · iShares Trust | 0.01% | 18,527 SH | Sept. 11, 2026 | Daily |
| NPFE · Elevation Series Trust | 0.00% | 9 NS | July 31, 2026 | N-PORT |
| BIV · VANGUARD BOND INDEX FUNDS | · | · | July 15, 2026 | Daily |
| BSV · VANGUARD BOND INDEX FUNDS | · | · | July 15, 2026 | Daily |
| BND · VANGUARD BOND INDEX FUNDS | · | · | July 15, 2026 | Daily |
| VUSB · VANGUARD BOND INDEX FUNDS | · | · | July 15, 2026 | Daily |
| VSDB · VANGUARD MALVERN FUNDS | · | · | July 15, 2026 | Daily |
| VCSH · VANGUARD SCOTTSDALE FUNDS | · | · | July 15, 2026 | Daily |
| VCIT · VANGUARD SCOTTSDALE FUNDS | · | · | July 15, 2026 | Daily |
| VCLT · VANGUARD SCOTTSDALE FUNDS | · | · | July 15, 2026 | Daily |
| VTC · VANGUARD SCOTTSDALE FUNDS | · | · | July 30, 2026 | Daily |
| BNDW · VANGUARD SCOTTSDALE FUNDS | · | · | July 30, 2026 | Daily |
| BNDX · VANGUARD CHARLOTTE FUNDS | · | · | July 15, 2026 | Daily |
| VCEB · VANGUARD WORLD FUND | · | · | July 30, 2026 | Daily |
BDX Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
rating · 20 analysts
BUY
Median target
$197.50
+0.6%
5 25.0%
Strong Buy
6 30.0%
Buy
9 45.0%
Hold
0 0.0%
Sell
0 0.0%
Strong Sell
12-Month Price Target
14 analysts · 2026-10-23Mean target $195.57 -0.4%
Now
Current price $196.39
Low$165.00
Mean$195.57
High$225.00
Peer comparison (GICS sub-industry) Key metrics vs sector peers
FY basis, prices as of each company's last fiscal year-end close.
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| BDX | · | 25.3 | 8.2% | 7.7% | 6.5% | · |
| ABT | $250.18B | 33.7 | 5.7% | 14.7% | 13.1% | · |
| ISRG | $201.11B | 72.0 | 20.5% | 28.4% | 16.7% | 66.0% |
| SYK | $134.44B | 41.8 | 11.2% | 12.9% | 15.1% | 64.0% |
| BSX | · | 49.1 | 19.9% | 14.4% | 12.6% | 69.0% |
| EW | $49.50B | 46.6 | 11.6% | 17.7% | 10.6% | 78.0% |
| IDXX | $53.93B | 51.7 | 10.4% | 24.6% | 69.2% | 61.8% |
| RMD | $28.11B | 18.7 | 9.8% | 26.9% | 23.6% | 61.1% |
| GEHC | · | 18.0 | 4.8% | 10.1% | 22.1% | 40.0% |
| DXCM | $25.54B | 31.8 | 15.6% | 17.9% | 31.4% | 60.1% |
| ZBH | $28.66B | 25.3 | 7.2% | 8.6% | 5.6% | · |
Latest News Recent headlines mentioning this company
Jim Cramer on Becton, Dickinson: “I Think You Buy Some and Then You Wait”
Yahoo Finance ·
Is Wall Street Bullish or Bearish on Becton, Dickinson and Company Stock?
Yahoo Finance ·
Becton Dickinson (BDX) Delivers Solid Q2 Performance, Barclays Lifts Target
Yahoo Finance ·
Jim Cramer on Becton, Dickinson: “The Company Showed Excellent Execution Across the Board”
Yahoo Finance ·
Becton, Dickinson and Company Q2 Earnings Call Highlights
Yahoo Finance ·
RBC Trims Becton Dickinson (BDX) Outlook despite Stable MedTech Demand
Yahoo Finance ·
My Metrics Your personal watchlist — selected rows from Full Fundamentals
Pick the metrics that matter to you — click the + next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Source: SEC 10-Q filed Aug 6, 2026